Anaptys Posts $177M Q2 Profit on Jemperli Royalties, Flags Key FDA Decisions
ANAB has more than doubled off its 52-week low of $13.658.
Summary
AnaptysBio reported Q2 2026 net income from continuing operations of $177.3 million, driven by a $181.5 million tax benefit from releasing a valuation allowance. Collaboration revenue rose to $27.5 million, up from $22.3 million a year ago, as Jemperli royalties grew 25% year-over-year. GSK's Jemperli hit $331 million in Q2 global sales, up 26%, and the company reiterated expectations for over $390 million in annualized royalties by 2029. Key upcoming catalysts include an FDA decision on Jemperli in rectal cancer (PDUFA February 2027), a Quimilza approval decision in GPP (December 12, 2026), and a post-trial hearing in the GSK/Tesaro litigation on October 20, 2026. Cash stood at $164.1 million as of June 30, 2026, down from $211.6 million at year-end 2025, with no shares repurchased under the $100 million buyback plan. The company completed its spin-off of First Tracks Biotherapeutics in April 2026 and changed its fiscal year-end to June 30.
At the time of this announcement, ANAB was trading at $55.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $13.66 to $72.36. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.